Weakness

Higher dependency on transaction revenue (options revenue) to drive profitability Negligible market share in the commodity segment  Impact of co-location case on overall profitability.

Opportunities

Diversification of revenue from other segments to reduce dependency

Structural growth in capital markets (growth in Demat accounts, PAN cards, NSE active clients, etc.)

 Increasing financialization of household savings

Retail investor participation is on the rise, as the perception of Indian equity markets is evolving, with the younger generation believing that equity markets provide an opportunity to earn Alpha.

Threats

Technology risk and cyber security attacks

 Impending penalty on colocation case

Unfavorable regulatory interventions and decision

Good morning

OBEROI REALTY LIMITED Company details

Oberoi Realty Ltd is a real estate development company operating in Mumbai, focused on premium developments. The company's focus is residential projects, but they also have a diversified portfolio of projects covering segments of the real estate market, like commercial, retail, social infrastructure and hospitality projects. The company has developed over 47 projects at strategic locations across the Mumbai skyline aggregating ~13.6 million sq. ft of spaces (group entity including promoter group) with another 29.7 million sq. ft. (carpet area) in the making as of March 2024. They have aggressive plans for upcoming projects in various parts of Mumbai and other regions. In order to achieve the scalability required to undertake large developments, they outsource work to leading international and domestic consultants in the areas of architecture, design, engineering and construction. The company appointed Samsung C&T Corporation as its general contractor for the iconic high-rise mixed-use project in Worli Mumbai. Revenue from real-estate contracts is recognized over a period of time in accordance with the requirements of Ind AS 115 using the percentage of completion method.

The Group’s investment properties consist of 5 commercial projects in Mumbai. It consists of Commerz I, Commerz II, Oberoi International school (Goregaon), Oberoi International school (JVLR) and Oberoi Mall. Investment properties are rented to tenants and are not intended to be sold in the ordinary course of business. The company also has 269 keys of The Westin Mumbai Garden City (Hospitality segment) with an ARR (average room rate) of ₹12,224, RevPAR (revenue per available room) of ₹10,190 with 83% of occupancy in Q1 FY25

#SALES #GROWTH 5 Year CAGR: 11.7%

In FY24, the company booked 704 units across the carpet area of 10,74,825 sq ft with a booking value of ₹3,996 cr. The revenue registered during the year was ₹4,496 cr. The RERA carpet area sold during FY23 was 16.75 lakh sq ft. The average implied realization increased from ₹30,539/sf in FY23 to ₹37,449/sf (up by 22.6% YoY) in FY24 which is largely due to the release of high-rise inventory. The company has launched ‘Forestville’ the first luxury residential project in Kolshet, Thane. It received occupation certificate for Sky city towers. It launched tower C in Elysian project at Oberoi Garden City. In Q1 FY25, company has booked 139 units across the carpet area of 2,10,783 sq ft with a booking value of ₹1,067 cr up by 124% YoY. The revenue registered was ₹1,405 cr up by 54% YoY. They received occupation certificate for Commerz III (2.4 million sq ft of carpet area) which is already 70% leased out. The company is gearing up for Pokhran, Thane launch along with towers in Goregaon and Borivali during the upcoming festive season.

#EBITDA #GROWTH 5 Year CAGR: 15.8%

In FY24, the EBITDA stood at ₹2,410 cr which increased by 14% YoY. This was due to higher realizations. In Q1 FY25, the EBITDA registered were ₹815 cr regsitering a growth of 72% YoY.

#PAT #GROWTH 5 Year CAGR 18.8%

In FY24, ₹1,918 cr and is not inclusive of the profit with JV of ~₹9 cr. In Q1 FY25, the PAT was at ₹582 cr up by 82% YoY.

#EBITDA #MARGIN

In FY24, EBITDA margin was 53.6% and the EBIT margin was 97.1% Rental, Residential segment was 48.3%, 39.4% hospitality and -13.5% in Property management services. Positive impact of better gross margin of 53% (v/s 50% in FY23) on account of mix. In Q1 FY25, EBITDA margin stood at 58% whereas, the EBIT margin was 91.7% for Rental, Residential segment was 54.6%, 39.8% hospitality and -18.9% Property management services.

#PAT #MARGIN

In FY24, the margin was 43% v/s 40% in FY23. In Q1 FY25, the PAT margin was at 41.4% v/s 35.1% in Q1 FY24.

#Companies #management

The management is led by Mr. Vikas Oberoi who is involved in the formulation of strategies and concentrates on the growth and diversification plans of the company. The company continues to look for prospects of expansion beyond the MMR region which will give further growth to the sustainability of business momentum and will provide value to all the stakeholders. It continues to focus on expanding annuity portfolio and to capitalize opportunities in the residential sector.

#Sectorial #Potential

The market size of India’s real estate sector is expected to reach USD 1 trillion by FY 2030 and the market is projected to increase at a CAGR of 19.5%. The market is anticipated to reach USD 650 Billion by FY 2025 and contribute 11-13% of the country’s GDP. • Since 2016 there have been various reforms which have impacted the real estate sector, from demonetization to RERA and GST which have started showing its impact and enhanced the transparency in the sector. The Government has also introduced ULPIN (Unique land parcel identification number) by the states for IT-based land management record to ensure higher transparency in the system. Source : Knight Frank. • Mumbai, being the largest real estate market in the country is set for a major boom, which will further add to the overall surge. For close to 5 years, Mumbai has resembled a gigantic construction site. A new coastal road, a metro rail and a trans harbor link are among the many ongoing infrastructure projects that are meant to transform India’s commercial capital into a modern and efficient city. As these projects complete over the next few years, new micro markets will open in and around Mumbai, as commuting would become easier. That will boost real estate development further. • Q1 CY24 witnessed a decent increase in new housing launches across the top 7 cities in India. A total OF ~1,10,900 residential units were launched, representing a year-over-year growth of 1% compared to Q1 CY23 (1,09,600 units launched). However, there was a slight quarter-over-quarter decrease of 6% from Q4 CY23 (1,17,400 units launched). MMR (Mumbai Metropolitan Region), Hyderabad, Pune, and Bengaluru were the key contributors to the surge in new launches, collectively accounting for 83% of the total supply addition. (source: Anarock) • The mid segment (₹40 lakh - ₹80 lakh) continued to dominate new housing supply, holding a significant market share of 33% in Q1 2024. The premium segment (₹80 lakh - ₹1.5 crore) and the affordable segment (less than ₹40 lakh)

Oberoi Realty 1300-1510
Expected level 1900
Support 1200

1340 to 1600+🚀Long term level hit 😍

Good morning

Sun Pharmaceuticals Company Details Report

Sun Pharmaceuticals is Leading global specialty generic company Global presence Operates in over 100 countries Diversified business Specialty portfolio, branded generics, generics & APIs Global Specialty Fast growing. Focused therapy approach. US Generics 12th largest in US generics market## India Largest pharma company in India** Emerging Markets Operating at scale in over 80 countries Rest of World Expanding presence in Ex-US developed markets R&D Global clinical trials. Early-stage novel R&D. Generic R&D 41 Manufacturing facilities Manufacturing capabilities across injectables, sprays, ointments, creams, liquids, tablets and capsules Quality compliance Several facilities approved by global regulators incl. USFDA Employees 43,000+ global employee base #

Sales Growth

ROCE & ROE

Business operations US FORMULATION


FY24 sales: Rs 153,493 mn  Specialty & Generics. Over 590 approved products  Large part of Specialty sales in the US. Dermatology, Ophthalmology and Onco Dermatology  12th largest generics company in US*, strong pipeline